Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin in NASH (RiFL)
NCT01355575Phase 4Terminated
- Sponsor
- Imperial College London
- Start
- May 2011
- Primary completion
- Sep 2012
- Countries
- 1
01
Overview
A Phase 4 trial of rifaximin in Nonalcoholic steatohepatitis (NASH), sponsored by Imperial College London. Started May 2011; status: terminated.
02
Drugs
rifaximin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT01355575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01355575.